In the present work, we developed the small-sized and high-efficient targeted nanobubble formulation, which carried the anti-PSMA nanobody, to verify the hypothesis that nanobody-coated nanobubbles can enhance the diagnostic value of ultrasound in prostate cancer. Here, FOLH1 is linked to prostate carcinoma.